TOTAL: $12.25M
Year to Date: $396.28M
Company
(Symbol)#*		 Partner
(Country)		 Amt.
(M)		 Triggering
Event		 Details (Date)
ArQule Inc.
(ARQL)		 Wyeth ND Milestone payment Triggered by the filing of an IND by Wyeth to begin testing of a compound for Alzheimer's disease (4/18)
Array
BioPharma
Inc. (ARRY)		 Genentech Inc. (NYSE:DNA) ND Milestone payment Triggered by nomination of a clinical candidate from their oncology collaboration and its advancement into regulated safety testing (4/17)
Array
BioPharma
Inc. (ARRY)		 AstraZeneca plc (UK) $1 Milestone payment Triggered by AstraZeneca's selection of a third compound for their small-molecule MEK anti-cancer program, from their collaboration that began in December 2003 (4/10)
Inspire
Pharmaceuticals
Inc. (ISPH)		 Santen Pharmaceutical Co. Ltd. (Japan) $1.25 Milestone payment Triggered by Santen's completion of Phase II clinical testing of diquafosol, for treating ocular surface diseases (4/19)
Karo Bio
AB (Sweden;
SSE:KARO)		 Wyeth ND Milestone payment Triggered by selection of a clinical development candidate in their LXR modulator program in atherosclerosis (4/20)
Modular
Genetics Inc.*		 Monsanto Co. ND Milestone payment Triggered by completion of one-year milestones in their three-year deal centered on protein optimization in agriculatural applications (4/24)
Pharmacopeia
Drug Discovery
Inc. (PCOP)		 Schering-Plough Corp. ND Milestone payment Triggered by Schering-Plough's selection of a compound from their collaboration for further development for treating respiratory disease (4/11)
Vertex
Pharmaceuticals
Inc. (VRTX)		 Merck & Co. Inc. $10 Milestone payment Triggered by initiation of a Phase II program for VX-680, which targets Aurora kinase, for treating cancers (4/5)
Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
* Private company.
Currency conversions are based on exchange rates at the time of the deal.
ND = Not disclosed.
NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange.